Primary Immune Deficiency Disorder Clinical Trial
Official title:
Towards Identification of New Inborn Errors of Immunity by Whole Exome/Genome Sequencing
Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome
sequencing.
Transcriptome analysis of patients with molecularly undetermined PID.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | August 15, 2025 |
Est. primary completion date | August 15, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with primary immunodeficiency (PID) - Male and Female participants 0 years to adult age (any) - Written informed consent by the participant after information about the research project Exclusion Criteria: - Secondary immunodeficiency - Refusal to enter the study |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Children's Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of the genetic defects | Whole exome/Genome sequencing will be done to identify new mutations leading to immunodeficiency | 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03939533 -
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
|
Phase 3 | |
Recruiting |
NCT03266640 -
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
|
Phase 2 | |
Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
Completed |
NCT01859754 -
Octagam 5% Versus Comparator Post Marketing Trial
|
||
Recruiting |
NCT03148028 -
Immunological Characteristics of Patients With PID and IBD
|
N/A | |
Active, not recruiting |
NCT04354818 -
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
|
||
Completed |
NCT03988426 -
Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
|
Phase 3 | |
Completed |
NCT01888484 -
Study of Octanorm Subcutaneous IG in Patients With PID
|
Phase 3 | |
Completed |
NCT01131858 -
Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency
|
Phase 1/Phase 2 | |
Completed |
NCT03211689 -
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
|
N/A | |
Terminated |
NCT01883921 -
Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
|
||
Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
Completed |
NCT02327351 -
TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
|
Phase 2/Phase 3 | |
Completed |
NCT03618147 -
Primary Immunodeficiency in Kuwait
|
||
Recruiting |
NCT04197596 -
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03422614 -
Pathophysiology of Inborn Immunodeficiencies
|
N/A | |
Completed |
NCT02888535 -
Intensive Care Unit and Secondary and Primary Immune Deficiency
|
||
Recruiting |
NCT04232085 -
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT03037359 -
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
|
||
Completed |
NCT03069079 -
Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study
|
N/A |